DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-06-09 08:55 |
DBV Technologies annonce un financement par placement privé d'un montant de 194…
|
French | 182.8 KB | ||
| 2022-06-09 08:55 |
DBV Technologies Announces Private Placement Financing of $194 Million
|
English | 182.3 KB | ||
| 2022-06-07 22:30 |
DBV Technologies annonce les résultats positifs de l’étude de phase 3 EPITOPE m…
|
French | 256.6 KB | ||
| 2022-06-07 22:30 |
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial …
|
English | 245.4 KB | ||
| 2022-05-17 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 128.7 KB | ||
| 2022-05-17 22:30 |
Monthly information regarding the total number of voting rights and total numb…
|
English | 159.8 KB | ||
| 2022-05-12 22:30 |
DBV Technologies annonce les résultats de son Assemblée générale ordinaire et e…
|
French | 130.7 KB | ||
| 2022-05-12 22:30 |
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary Gener…
|
English | 125.1 KB | ||
| 2022-05-12 15:01 |
Franchissement de seuils
|
French | 270.0 KB | ||
| 2022-05-05 01:30 |
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq th…
|
English | 180.3 KB | ||
| 2022-05-02 23:00 |
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
|
English | 150.9 KB | ||
| 2022-05-02 23:00 |
DBV Technologies met en place un programme At-The-Market (ATM) sur le Nasdaq
|
French | 170.6 KB | ||
| 2022-05-02 22:00 |
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Fi…
|
English | 258.1 KB | ||
| 2022-05-02 22:00 |
DBV Technologies fait le point sur le développement de ses activités et annonce…
|
French | 293.7 KB | ||
| 2022-04-21 22:30 |
Assemblée Générale Mixte du 12 mai 2022
|
French | 136.6 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
